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Potency and selectivity of a Urokinase-Activated recombinant 
Anthrax Toxin to acute myeloid leukemia (AML) cells 
 
Manal El Darwich 
ABSTRACT  
Acute myeloid leukemia (AML) is a disorder characterized by uncontrolled mitogenetic 
activation and proliferation of hematopoietic precursor cells. Up to 30 % of adult 
patients with AML do not achieve complete remission when treated using 
chemotherapy. In addition, severe side effects usually limit the efficacy of available 
therapeutic approaches. As a result, novel tumor-selective therapeutics capable of 
targeting and eliminating AML blasts while sparing normal cells are urgently needed. In 
this study, we determine the potency and selectivity of an engineered, urokinase-
activated recombinant anthrax fusion toxin (PrAgU2/FP59) on a panel of 9 AML cell 
lines and on normal progenitor bone marrow blasts. All 9 AML cell lines tested were 
sensitive to PrAgU2/FP59 while normal progenitor, bone marrow blasts were not, 
demonstrating the potency and selectivity of this tumor-targeted approach. Cytotoxicity 
of PrAgU2/FP59 appeared to be non-apoptotic and is dependent on the expression of an 
active cell surface urokinase plasminogen activator system (uPA/uPAR) system. 
Targeting the urokinase system, a protease overexpressed on AML cells, appears to be a 
promising approach for the development of AML-specific therapeutics. 
Keywords: AML, PrAgU2/FP59, dual selectivity, apoptosis, anthrax toxin.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1  Acute Myeloid Leukemia 
Acute myelogenous leukemia (AML) is the result of the constitutive mitogenetic 
activation of hematopoietic stem cells. According to the American Cancer Society, the 
expected number of new cases of leukemia is 54,270 in 2015 with 24,450 expected 
deaths from leukemia in the United States only. They also estimate about 10,460 deaths 
from AML specifically and almost all will be adults. It has been shown in vitro that 
multiple mutations must take place to end developing AML (Ferrara & Schiffer, 2013). 
This disorder leads to the disruption of normal differentiation and to the excessive 
proliferation of immature hematopoietic cells known as blasts (Perl & Caroll, 2007). 
More than 20% of blasts in the bone marrow are considered a characteristic of AML 
(Kumar, 2011). With time the increasing number of blasts will cause them to accumulate 
in the bone marrow, blood and organs. These alterations will interfere with normal 
production and differentiation of blood cells such as generating mature red blood cells, 
neutrophils, platelets and monocytes. These changes might cause anemia, neutropenia 
and thrombocytopenia which is characterized by bleeding (Ferrara & Schiffer, 2013; 
Villela & Bolañeos-Meade, 2011). AML can also result from the exposure to DNA-
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damaging reagents, such as chemotherapy, while treating other types of malignancies 
(Tawana et al., 2013). Treatment with cytotoxic agents increases the risk for developing 
AML in up to 15% of the patients usually treated for solid cancer. There are two types of 
genetic mutations correlated with chemotherapy which cause AML: drugs such as 
anthracyclines and epipodophyllotoxins that target topoisomerase II can cause 
cytogenetic abnormalities at the MLL gene locus at chromosome 11q23 within months 
to two years of treatment, while alkylator agent-induced disease cause myeolodysplastic 
syndrome with complex deletions in chromosomes 5 and 7 might occur 5 to 6 years after 
exposure. These chemotherapy induced diseases are mostly observed in patients older 
than 65 who usually represent high comorbidities (Ferrara & Schiffer, 2013). AML 
progresses rapidly, it will cause fatal infection, bleeding or organ infiltration. Bone 
marrow failure is the most common cause of death, and its main symptom is infection, 
while organ infiltration fatality becomes more powerful as the disease progresses. 
Incidence of AML is expected to become higher with the coming years with the aging 
population: for instance there are 2000 new cases of AML every year in UK (Tawana et 
al., 2013), while in the US, the incidence is 3.5 cases per 100000 (Villela & Bolañeos-
Meade, 2011).  The expected cure rate for AML is 30 to 40% depending on the 
biological characteristics of the leukemic clone (Villela & Bolañeos-Meade, 2011). 
 
1.2  Current therapies of AML 
AML has a reduced prognosis and it is considered to be poorly curable due to the 
high percentage of secondary AML associated with multidrug resistance mechanisms. 
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Conventional treatment for AML includes two phases: induction and consolidation. 
While the purpose of induction is to achieve complete remission, the aim of 
consolidation is to eliminate all residual leukemia via stem cell transplantation or 1-4 
cycles of chemotherapy using ara-C combined with anthracycline or anthracenedione 
(Ferrara & Schiffer, 2013; Roboz, 2011). Since all patients become pancytopenic and 
can have fever and infections after the first induction, only eligible patients can undergo 
a second course of induction on the forteenth day. Usually, a second induction of drugs 
is favored in only some young patients due to the risk of severe pancytopenia (Ferrara & 
Schiffer, 2013).  In a meta-analysis study, it has been shown that patients who are less 
than 60 years old have a long term survival rate with high ara-C and from doubling 
daunorubicin while patients older than 50 years do not benefit from these changes 
(Roboz, 2011). Blocking signaling pathways as therapy has been applied against specific 
receptors such as receptor tyrosine kinase or against intracellular pathways. As shown in 
figure 1, different drugs have been used to treat patients with AML. Tipifarnib acts as a 
nonpeptidomimetic farnesyltransferase inhibitor (FTI), Sorafenib is used against solid 
tumors and it inhibits many pathways especially Raf kinase, Lestaurtinib and 
Midostaurin inhibit FLT3 receptors, while Everolimus and cytarabine are thought to be 
capable of inhibiting the PI3K/AKT/mTOR pathway. And yet many patients relapsed 
after treatment or had complete remission without complete platelets recovery (Villela & 
Bolañeos-Meade, 2011). 
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Figure 1.1: Drugs inhibiting at different stages the pathways leading to AML (Villela & 
Bolañeos-Meade, 2011).   
 
After complete remission is achieved, all patients will relapse without 
consolidation. The type of treatment following induction depends on the status of the 
organs of the patient. The high dose ara-C consolidation method is suggested in patients 
with NPM1 and CEBPA mutations in the absence of FLT3-ITD mutations (Roboz, 
2011). Patients with KIT mutations are mostly considered for allogeneic stem cell 
transplant while patients with NPM1 mutation respond poorly to this type of therapy. 
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Autologous stem cell treatment is still not very successful most possibly due to graft 
contamination with residual leukemia. The relapse rate following stem cell transplant 
depends highly on the karyotype and on the type of mutation (Ferrara & Schiffer, 2013; 
figure 2).   
Another novel therapy relies on epigenetic gene regulation which refers to the 
control of transcription that is not controlled by the DNA sequence but rather via DNA 
methylation or a variety of histones modifications such as acetylation, phosphorylation, 
and methylation. The use of hypomethylating or epigenetic agents such as decitabine 
and azacitidine have been adopted for the treatment of older patients with AML since 
they have a low chance of clinical benefit from extensive chemotherapy (Ungewickell, 
& Medeiros, 2012).  
It has also been shown that patients with core binding factor AML including 
t(8;21) and abn16q22 have more than 60% chance of cure rate with high dose cytarabine 
however patients with other types of translocations such as t(6;9) respond poorly to 
chemotherapy (Ferrara & Schiffer, 2013). Up to 70% of these patients treated with araC 
+ anthracycline induce remission of cancer after treatment due to the persistence of 
chemotherapy resistant blasts (Menezes et al., 2005). Patients who are less than 60 years 
old enter complete remission in more than 70% of the cases but more than half of them 
will relapse with a poor long term survival (Tawana et al., 2013).  Administration of 
intensive induction therapy requires patients to be hospitalized for 4 to 5 weeks which 
increases the risk of infections especially due to the prolonged neutropenia. In addition, 
patients with AML develop adverse symptoms when treated with chemotherapy such as 
nausea, vomiting and diarrhea like any type of cancer treated as such. 
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Treatment with chemotherapy overall results have been very disappointing in 
showing a consistent improvement among most patients. FLT3 is the only mutation that 
can be pharmacologically targeted (Ferrara & Schiffer, 2013). On the other hand, 
allogeneic stem cell transplantation is very limited to a certain type of patients. 
Therefore, a more efficient cure must be manufactured using advanced drugs that target 
the mutations within malicious cells without distressing the normal ones. Such definite 
drugs will minimize the disturbing impact caused by chemicals and harmful rays 
administered during chemotherapy and radiation (Kumar, 2011). More potent 
therapeutics must be manufactured in order to selectively eliminate AML cells without 
causing organ damage. One such class of therapeutics is recombinant toxins. 
 
1.3  The recombinant toxins  
1.3.1  Recombinant toxins 
Recombinant toxins are genetically engineered proteins which consist of a toxin 
fused to a ligand that binds selectively to a target cell (Kreitman, 2003).  
When the ligand is either an antibody or a growth factor it becomes a 
recombinant immunotoxin such as one recombinant toxin that contains the human 
interleukin-2 and the truncated diphtheria toxin has been approved for use in cutaneous 
T-cell lymphoma (Kreitman, 2009). Novel studies include the development of 
recombinant toxins vaccines such as a vaccine assembled from two recombinant 
fragments of toxin B produced by Clostridium difficile (Karczewski et al., 2014).  
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Recombinant toxins used for the treatment of cancer are expected to increase in 
number in the coming years. They are usually made of either a growth factor or a 
recombinant fragment of a monoclonal antibody fused to a truncated bacterial toxin, 
derived either from Pseudomonas exotoxin or from diphtheria toxin (Kreitman, 2003). A 
recombinant toxin targeted against adult T-cell leukemia consists of a fragment from 
Pseudomonas exotoxin (PE38) fused to CCR4 ligand, has shown high efficacy in 
eliminating infected cells. This recombinant toxin proved to vigorously control HTLV-1 
infection in vitro and in vivo (Hiyoshi et al., 2015). Hence, AML could be also 
eliminated by using similar recombinant toxins. One such recombinant toxin has 
previously been developed to be able to recognize AML cells hence causing cell death to 
malignant cells only without affecting normal ones (Abi Habib et al., 2004).  
 
1.3.2  Anthrax Lethal toxin (PrAg/LF) 
The Bacillus anthracis is a spore forming gram-positive bacterium that secretes 
the anthrax toxin made of three polypeptides that comprise: protective antigen (PrAg) 
the binding component, and enzymatic moieties the edema factor (EF) and lethal factor 
(LF). PrAg, LF and EF act together to suppress the host’s immune system (Wein et al., 
2012). This toxin targets mammalian cells by originally binding on the tumor endothelial 
marker 8 (TEM-8), capillary morphogenesis gene 2 (CMG-2) and integrin ß1 (ITGB1) 
product cell surface receptors, through PrAg (Abi Habib et al., 2005; Martchenko et al., 
2012). It is then proteolytically activated by cell surface furin which releases the amino-
terminal 20 KDa peptide (PrAg20). At this moment the remaining carboxy-terminal 
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PrAg63 binds the cell to form a heptamer. Oligomerization of PrAg63 produces up to 
three binding sites for EF or LF, enzymatic moieties which cannot bind to the 
monomeric form of PrAg63, and induces their internalization into endosomes by 
endocytosis through a lipid raft-mediated clathrin-dependent process. Once the 
endosomes are acidic, the PrAg63 heptamer forms a channel through the endosomal 
membrane to allow the translocation of LF and EF into the cytosol. LF is a zinc-
dependent metalloprotease that cuts mitogen-activated protein kinase kinases 
(MAPKKs) in their amino-terminal regions and causes cell cycle arrest and cell death. 
On the other hand, EF is a calcium and calmodulin-dependent adenylatecyclase that 
causes impairment of phagocytosis (Abi Habib et al., 2006; Liu et al., 2009). The MAPK 
pathway has been successfully targeted in AML using anthrax toxin. Previous studies 
had shown that anthrax lethal toxin is not sensitive to a majority of normal human cell 
lines such as cardiac microvascular endothelial cells, umbilical vein endothelial cells, 
cardiomyocytes, lung fibroblasts, astrocytes, hepatocytes, renal proximal tubule 
epithelial cells, renal cortical epithelial cells, skeletal muscle cells and lymphocytes. The 
few cells that were sensitive to the anthrax toxin were restricted to monocytes, coronary 
artery endothelial cells, pulmonary artery endothelial cells, lung microvascular 
endothelial cells, and renal mesangial cells (Abi-Habib et al., 2005). In another study, 
human melanocytes did not show cell death when incubated with anthrax lethal toxin for 
8 days (Koo et al., 2002). The anthrax lethal toxin is, therefore, a specific toxin that only 
targets a limited number of normal human cells that depend solely on the MAPK 
pathway; therefore it can be considered an asset for treating selectively tumor cells such 
as AML cells. Furthermore, PrAg/LF can be modified by altering different sequences of 
its protective antigen moiety or by replacing the catalytic domain of lethal factor. 
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Figure 1.2: A model showing the mechanism of cell binding and internalization of 
anthrax lethal toxin.  
 
1.3.3  PrAg/FP59 
The amino terminal sequence of LF and the amino terminal sequence of EF 
constitute the PrAg heptamer-binding domain. The zinc metalloprotease domain of LF 
and the edema factor domain can be substituted with another bacterial toxin enzymatic 
domain as long as it contains the N-terminal 254 amino acid of anthrax toxin lethal 
factor (LFn). The bacterial catalytic domain that was used to replace the catalytic 
domain of LF is the catalytic domain of Pseudomonas aeruginosa exotoxin A, which 
ADP-ribosylates elongation factor 2 EF-2 leading to the inhibition of protein synthesis. 
The resulting fusion protein, termed FP59 (due to its molecular weight), is therefore, a 
fusion of the PrAg-binding domain of LF and the catalytic domain of Pseudomonas 
aeruginosa exotoxin A (Liu et al., 2009; Bachran et al., 2013). Once in the cytosol, the 
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catalytic domain of Pseudomonas aeruginosa exotoxin A (PEIII) will transfer ADP-
ribose to eukaryotic elongation factor 2 (eEF2), leading to protein synthesis inhibition 
and subsequent cell death (Bachran et al., 2013). FP59 is a drug with a more potent and 
a wider range of activity than LF since, once inside the cytosol, it is cytotoxic to all cells 
(Abi-Habib et al., 2006). The PrAg/FP59 toxin is highly effective in specifically 
activating the cell surface PrAg and delivering of PEIII in the cytosol, it has been 
positively tested for a number of tumor types and it is expected to be active on most 
solid tumors (Bachran et al., 2014). Since FP59 has a much wider and potent toxicity 
than LF, therefore it is essential to make it more selective to AML cells hence reducing 
its effect on normal cells 
 
1.3.4  The uPA/uPAR system 
Several types of solid tumors overexpress the urokinase plasminogen activator 
(uPA), which increases their metastatic potential. However, the uPA system is rarely 
present on normal cells (Abi-Habib et al., 2006). AML blasts overexpress uPA and 
uPAR and have been successfully targeted using the recombinant diphtheria toxin (Abi 
Habib et al., 2004). Up to 73% of AML patients have been shown to express the uPA 
protease system (Atfy, EIssa & Salah, 2012). The uPA system is composed of a serine  
protease (uPA), its receptor, which is a urokinase-type plasminogen activator receptor- 
uPAR or CD87, and two main inhibitors, the plasminogen activator inhibitor 1 (PAI 1) 
and activator inhibitor 2 (PAI 2) (Béné et al., 2004). uPA is a protease that regulates the 
activation of plasminogen to the serine protease plasmin, causing the rearrangement of 
11 
 
the extracellular matrix and yielding to cell migration (Alfano et al., 2003). The uPAR is 
a highly glycosylated glycosyl-phosphatidyl inositol (GPI) that is anchored on the cell 
surface and binds to uPA which is generated endogenously or exogenously (Béné et al., 
2004; Prager et al., 2004).  
The activate uPA/uPAR system slices plasminogen into plasmin which causes 
the degradation of the extracellular matrix and subsequently tissue migration, 
invasiveness and metastasis. The inactive single chain precurseur pro-uPA is made of 
two parts: an amino-terminal fragment and a carboxy-terminal catalytic domain (Alfano 
et al., 2003). uPA has proteolytic functions when it converts plasminogen and non-
proteolytic functions when it binds to uPAR (Alfano et al., 2003). It all begins when the 
N-terminal domain of pro-uPA, binds to its receptor uPAR. This will cause pro-uPA to 
be activated and to be able to break down plasminogen into plasmin, which activates 
pro-uPA to uPA and prometalloproteinases to active metalloproteinases (figure 2) 
(Prager et al., 2004). The trimeric uPA/uPAR complex affects cell migration, adhesion, 
differentiation and proliferation (Alfano et al., 2003). 
The inhibitors can bind to the active or inactive form of uPA. PAI1 acts by 
binding to uPAR and changes its characteristics, and then the uPA/uPAR bound to PAI1 
becomes able to bind to alpha-2-macroglobulin which causes the internalization of the 
complex. The complex will then break down into two parts uPA-PAI1 and the receptor 
uPAR. The lysosomes will degrade uPA-PAI1 while the uPAR is recycled to the cell 
surface. Therefore, PAI1 regulates the activity of uPAR and its distribution on the cell 
surface. The uPA/uPAR complex is unaffected by the plasminogen activator inhibitor-1.   
Under normal conditions the uPA/uPAR system is only expressed when physiologic 
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processes need rapid division of cells such as wound healing and tissue remodeling 
(Béné et al., 2004; Abi Habib et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: A model describing the mode of activation and action of the uPA/uPAR 
protease system (Alfano et al., 2003). 
 
1.3.5  PrAgU2/FP59 
Since uPA and uPAR are poorly expressed in normal cells and overexpressed on 
cancer cells, particularly AML, we have replaced the furin activation site of PrAg 
164
RKKR
167
 with a urokinase activation site termed U2 
163
PGSGRSA
169
. PrAgU2 when 
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used in combination with FP59 constitutes a novel, potent and tumor selective toxin. 
PrAgU2/FP59 binds to all cells through the ubiquitously expressed ANTXRs but is now 
only activated on AML cells by active uPA/uPAR (Liu et al., 2009). In normal cells, the 
expression of uPA and uPAR is induced in response to tissue injury, playing a major 
role in tissue repair and remodeling (Liu et al., 2003). uPA is initially secreted in a single 
chain inactive form, once cleaved by plasmin into a double chain it becomes active. 
Both the active and inactive form of these serine protease bind to uPAR. Potency of 
PrAgU2/FP59, therefore, depends on the expression and activity of all the following 
markers; anthrax toxin receptors (ANTXRs), uPAR and uPA. The presence of ANTXRs 
is essential to the potency of PrAgU2/FP59 independently of the other markers uPA and 
uPAR making ANTXR the primary binding site of PrAgU2. In the absence of uPAR cell 
lines are not sensitive to the recombinant toxin PrAgU2/FP59 even upon addition of 
excessive amount of exogenous pro-uPA (Abi Habib et al., 2004; Liu et al., 2009). In a 
previous paper it has been shown that PrAgU2/FP59 is toxic to a wide range of tumors 
such as non-small cell lung tumor, prostate tumor, basal-like breast tumor, pancreatic 
tumor, and basal-like breast tumor. It has also been noted in this study that the tumor cell 
lines that did not respond to PrAgU2/FP59 became sensitive upon adding exogenous 
pro-uPA. Therefore, this toxin is highly selective since most normal human cells tested 
were resistant (Abi Habib et al., 2004). In another study of B16 mice with melanoma 
were treated with high dose of PrAgU2/FP59, these mice suffered from ulcerations of the 
anal region and edema of the small intestine since uPA and uPAR are expressed in the 
villi under normal conditions. No histologic marks of toxicity were observed in the lung, 
kidneys, liver, heart and spleen. Using an anti-inflammatory steroid drug such as 
dexamethasone, while administering PrAgU2/FP59 alleviated the systemic toxicity 
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caused by the recombinant toxin and reduced mortality to 1%. In the same study, it was 
shown that PrAgU2/FP59 has significant antitumor effect after intra-peritoneal 
administration in colon and breast cancer (Rono et al., 2006). In addition, some studies 
have shown the high potential and selectiveness of PrAgU2/FP59 against tumors in vivo 
(Kassab et al., 2013). uPAR is highly expressed by macrophages, budding cancer cells in 
colon cancer, in squamous cell carcinomas, making these types of tumors such as lung, 
head, neck, cervical and esophageal squamous cell carcinomas a good candidate for 
PrAgU2/FP59 based therapy aiming at selecting and treating the cancer cells directly 
(Rono et al. 2006).  The purpose of the novel studies is to switch cancer treatment into 
becoming tumor-selective; such as targeting BCR-Abl mutants in chronic myeloid 
leukemia and targeting Her2-neu over-expression in breast cancer patients (Druker et al., 
1996; Pegram et al., 1998). It is supposed that the use of such toxins will lead to a more 
specific treatment with a reduction of the adverse symptoms caused by traditional 
chemotherapy and radiation and a reduction in the relapse percentage among patients. In 
addition, such recombinant toxins can be modified to become more selective to AML 
cells; hence they can only be activated in hematopoietic cells harboring mutations 
leading to uncontrolled proliferation. 
 
1.4  Cell death 
Targeted therapies usually try to approach cell death in order to clear diseased 
cells. Cell death is mainly classified into different types based on morphological and 
biochemical changes occurring within the cell. Generally, the most important 
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mechanisms related to cell death are apoptosis, necrosis, and autophagy (figure 2). 
Apoptosis is an organized programmed cell death that is activated by series of caspases, 
a family of intracellular cysteine protease (Edinger & Thompson, 2004; Testa et al., 
2007). Necrosis, on the other hand, is an unorganized type of cell death that induces 
inflammatory response (Edinger & Thompson, 2004). Moreover, autophagy is a process 
mediated by lysosomes, which is responsible for intracellular degradation (Zhang, 
2015). Apoptosis is a major process that maintains tissue homeostasis, embryonic 
development and for the differentiation and function of hematopoietic and lymphoid 
cells (Testa et al., 2007). There are two types of caspases that control apoptosis: the 
initiator caspase, which act at the origin of the apoptosis process and the effector 
caspase, which act in cell death execution. There are two ways by which caspases are 
activated: the extrinsic pathway which is triggered by death receptors on the cell 
membrane and the intrinsic pathway which is activated by several intracellular and 
extracellular stresses such as growth factor deprivation, oncogene induction, DNA 
damage, hypoxia and cytotoxic drugs (Testa et al., 2007). The intrinsic factors induce 
biochemical events that lead to the degradation of the outer mitochondrial membrane, 
with the consequent release of cytochrome c and other pro-apoptotic molecules from the 
inner mitochondrial membrane into the cytosol. Factors leading to the deregulation of 
apoptosis disturb the complex balance between cell proliferation, cell survival and cell 
death initiating in most cases cancer and particularly leukemia. Furthermore, tumors 
caused by disruption of proteins involved in cell death signaling are frequently resistant 
to chemotherapy (Testa et al., 2007). In a recent study, Nutlins have been developed to 
target the overexpressed MDM2 in AML cells in order to inhibit p53 activation leading 
to the induction of apoptosis (Kojima et al., 2015). In another study, the combination of 
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sorafenib with cytarabine induced cell death in AML cell lines by lowering the apoptotic 
threshold of these cells making them more sensitive to the proapoptotic effect of other 
biological agents and chemotherapeutic (Zhang et al., 2008).  
 
Figure 1.4: Main types of cell death, apoptosis, necrosis, and autophagy. The process of 
cell death is classified into three classes: stimulation, regulation, and degradation (Esteve 
& Knecht, 2011). 
 
In previous studies, the use of PrAgU2/FP59 indicated a high potential approach 
in targeting urokinase expressing solid tumors (Abi Habib et al., 2004). In addition, 
inducing apoptosis in AML cells through targeted therapy would be considered as a 
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reversible way to overcome leukemia.  In the following study, we show the high 
selectivity and potency of the urokinase recombinant toxin PrAgU2/FP59 in AML cell 
lines. We also investigated the mechanism of cell death induced in the AML cell lines 
upon treatment with the recombinant toxin.  
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
2.1  Expression and purification of PrAg, PrAgU2 and FP59 
Recombinant anthrax proteins, PrAg (activated by furin), PrAgU2 (activated by 
the urokinase plasminogen activator), and FP59, were expressed and purified in the 
laboratory of Stephen H. Leppla at the National Institute of Allergies and Infectious 
Diseases (NIAID) of the National Institutes of Health (NIH) in Bethesda, MD, as 
described previously (Ramirez DM, 2002; Liu S., 2001).  
 
2.2  Cells and cell lines 
Human AML cell lines HL60, U937, ML1, ML2, Mono-Mac-1, Mono-Mac-6, 
TF1-vRaf, TF1-vSrc and TF1-HaRas were obtained from the American Type Culture 
Collection (ATCC) and grown as described previously in RPMI 1640 supplemented 
with 10% FBS and 5% penicillin/Streptomycin or in Iscove’s Modified Dulbecco’s 
Medium (IMDM) supplemented with 10% FBS and 5% penicillin/Streptomycin (ML1) 
at 37
o
C, 5% CO2 (Pellizzari et al., 1999). 
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Human CD34
+
 progenitor bone marrow blasts (PBMBs) were purchased from (Lonza, 
Basel, Switzerland) and grown in StemlineII
TM
 hematopoietic stem cell expansion 
medium (Sigma-Aldrich) supplemented with 10 ng/ml IL-3, 5 ng/ml granulocyte colony 
stimulating factor (G-CSF), 5 ng/ml granulocyte macrophage colony stimulating factor 
(GMCSF), 10 ng/ml stem cell factor (SCF), 10 µg/ml insulin and 100 µg/ml transferrin 
(Sigma-Aldrich), as described previously (Blair, Hogge, & Sutherland, 1998). 
 
2.3  Proliferation inhibition assay (Cytotoxicity) 
Sensitivity of human AML cell lines and Human CD34
+
 progenitor bone marrow 
blasts to PrAgU2/FP59 was determined using a proliferation inhibition assay 
(cytotoxicity) as described previously (Abi-Habib et al., 2005). We have also used a 
combination of the furin-activated PrAg with FP59 (PrAg/FP59) as a control for 
urokinase-independent cytotoxicity of FP59. Binding of FP59 to PrAg and its 
translocation into the cytosol are identical to those of PrAgU2, however, it is activated 
by the ubiquitously-expressed furin protease instead of the AML-specific urokinase 
plasminogen activator. Hence PrAg/FP59 is cytotoxic to all cells, with no tumor 
selectivity, and serves as control for the potency of FP59. Briefly, aliquots of 10
4
 
cells/well, in 100 l cell culture medium, containing a fixed concentration of 10-9 M 
FP59 were plated in a flat-bottom 96-well plate (Corning Inc. Corning, NY). Then, 50 l 
PrAgU2 or PrAg in media were added to each well to yield concentrations ranging from 
10
-8
 to 10
-13
 M. Following a 48 h incubation at 37
o
C/5% CO2, 50 l of XTT cell 
proliferation reagent (Roche, Basel, Switzerland) were added to each well and the plates 
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incubated for another 4 h. Absorbance was then read at 450 nm using a microplate 
reader (Thermo Fisher Scientific, Waltham, MA). Nominal absorbance and percent 
maximal absorbance were plotted against the log of concentration and a non-linear 
regression with a variable slope sigmoidal dose-response curve was generated along 
with IC50 using GraphPad Prism 5 software (GraphPad Software, San Diego, CA). All 
assays were performed at least twice with an inter-assay range of 30% or less for IC50.  
 
2.4  Cell cycle analysis 
The impact of treatment with PrAgU2/FP59 on the cell cycle of AML cells was 
determined using Propidium Iodide (PI)-staining on flow cytometry. Briefly, cells 
incubated with PrAgU2/FP59 (10
-8 
M), PrAg/FP59 (10
-8
 M) and FP59 alone (10
-9 
M) as a 
control in a 6-well plate (Corning Inc. Corning, NY) for 48 and 72 h at 37
o
C, 5% CO2, 
were harvested and fixed in 70% ethanol for a minimum of 24 h, at -20
o
C. Cells were 
then incubated in 500 µl PI staining solution (50 µg/ml) for 40 min at 37
o
C. Samples 
were then read on a C6 flow cytometer (BD Accuri, Ann Arbor, MI) and total cell DNA 
content was measured on FL2-A. Percent of cells in G0/G1, S and G2/M phase was 
determined in control cells and in cells treated with PrAgU2/FP59 and with PrAg/FP59 
following gating for the cell population on width versus forward scatter. 
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2.5  Analysis of Cell Cytotoxicity 
Determination of apoptotic versus non-apoptotic cell death was carried out using 
an Annexin V-fluorescin Isothiocyanate (Annexin V-FITC) and Propidium Iodide (PI) 
labeled apoptosis/necrosis detection kit (Abcam, Cambridge, MA) and a FITC-
conjugated active caspase inhibitor (ApoStat Apoptosis Detection Kit, R&D Systems, 
Abingdon, England) on flow cytometry. Briefly, 10
4
 cells/well were plated in 100 l 
media in a flat-bottom, 96-well plate and were incubated with either 100 l of medium 
alone (control cells) or medium containing three different concentrations of 
PrAgU2/FP59 or PrAg/FP59 (as described above under cell cycle analysis) for 24 and 48 
h at 37
o
C/5% CO2. Cells were then harvested and incubated with a FITC-conjugated 
annexin V antibody (2.5 mg/ml) and PI (5 mg/ml) in antibody binding buffer for 45 min 
at 37
o
C or incubated with 0.5 µg/ml of apostat for 30 min then harvested. Cells were 
then read using a C6 flow cytometer. Annexin V/PI data was analyzed on FL1-H versus 
FL2-H scatter plot and active caspases were detected on FL1-H. Unstained cells were 
used as negative control. Cells had to show positive annexin V staining, negative PI 
staining and positive active caspase staining to be considered apoptotic, while cells 
positive for both annexin V and PI staining and negative for active caspase staining were 
considered non-apoptotic. 
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2.6  Expression of uPAR 
Expression of the urokinase plasminogen activator receptor (uPAR) on AML cell 
lines was determined using single cell staining with a FITC-conjugated anti-uPAR 
antibody on flow cytometry as described previously. Approximately 10
6
 cells were 
incubated with a 1/100 dilution of a FITC-conjugated anti-uPAR mouse monoclonal 
antibody (Cell Signaling Technology, Danvers, MA) in antibody binding buffer for 1 h 
at 37ᵒC. Cells stained only with a FITC-conjugated mouse IgG were used as isotypic 
control. Samples were then analyzed using a C6 flow cytometer (BD Accuri, Ann Arbor, 
MI). The expression of uPAR was analyzed on FL1-H and compared with that of the 
isotopic control. Positivity for the presence of uPAR was determined using the ratio of 
fluorescence intensity (RFI) between the mean fluorescence intensity (MFI) of the uPAR 
stained cells and the MFI of the isotypic control. RFI > 2 was considered positive. RFI 
between 1.5 and 2 were considered slightly positive and RFI < 1.5 was considered 
negative. 
 
2.7  Blocking Assays 
Blocking assays were performed to test the ability of specific anti-uPA 
antibodies to block the cytotoxicity of PrAgU2/FP59 to uPAR-expressing AML cell 
lines. The same proliferation inhibition assays were performed as described earlier with 
the difference that in the blocking assays, 10 µg/mL monoclonal anti-uPA antibody 
(American Diagnostica) was added to a subset of cells upon plating. The rest of the 
assay proceeded as described above. Data was analyzed using GraphPad Prism V 
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software (GraphPad Software, San Diego, CA). The absorbance and the percent 
absorbance of controls were compared between the different treatment groups. 
 
2.8  Effect of the addition of pro-uPA 
This assay was performed to further demonstrate that the activity of 
PrAgU2/FP59 was dependent on the activation of uPA. Aliquots of 10
4
 cells were 
incubated in 100 μL medium (same as that used to grow the cells) in Costar (Corning, 
NY) 96-well flat-bottomed plates in duplicate. Exogenous human pro-uPA (American 
Diagnostica, Stamford, CT) was added to 36 wells of each duplicate plate (100 ng/mL in 
each well). Then, 50 μL PrAgU2 in medium was added to each column to yield 
concentrations ranging from 0.1 to 10 000 pM, and the cells were incubated at 37°C/5% 
CO2 for 24 to 48 hours (Abi-Habib et al., 2004). Data was analyzed using GraphPad 
Prism V software (GraphPad Software, San Diego, CA). The absorbance and the percent 
absorbance of controls were compared between the different treatment groups. 
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CHAPTER THREE 
RESULTS 
 
3.1  Cell Sensitivity to PrAgU2/FP59. 
3.1.1  Potency of PrAgU2/FP59 to AML Cell Lines 
The potency of PrAgU2/FP59 was determined on a panel of nine human AML 
cell lines using a proliferation inhibition assay (cytotoxicity). FP59 ADP-ribosylates 
elongation factor-2 (EF2) leading to the inhibition of protein synthesis and subsequent 
cell death; hence it is cytotoxic to all cells that express anthrax toxin receptors 
(ANTXRs) once it enters the cytosol. Potency of PrAgU2/FP59 to AML cell lines will, 
therefore, depend on their cell surface uPA/uPAR activity and their ability to activate 
PrAgU2 and deliver FP59 into the cytosol.  
           All 9 human AML cell lines were sensitive to PrAgU2/FP59 with IC50 values 
ranging from 2.0 to 414 pm and a more than 70% death at the highest concentration, 
indicating that AML cells do express uPA/uPAR and are effectively targeted by the 
urokinase-activated fusion toxin, PrAgU2/FP59 (table 3.1 and figure 3.1.1). The range 
and potency of PrAgU2/FP59 were similar to those of the furin-activated, non-tumor 
selective PrAg/FP59, which was used as a positive control for the potency of FP59 (table 
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3.1 and figure 3.1.1). Though the IC50 of PrAgU2/FP59 to some of the cell lines tested (5 
out of 9) was higher than that of PrAg/FP59, this data still demonstrates that the addition 
of a tumor-selectivity criterion, in the form of urokinase activation, did not affect the 
range and potency of this fusion toxin. This is expected because even though the 
expression and activity of the urokinase plasminogen activator protease system 
(uPA/uPAR) on AML cell lines is high, they may not reach the same levels as those of 
the furin protease system which is highly overexpressed and very active on all types of 
cells and tissues. 
   
A) 
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Figure 3.1.1: Cytotoxicity of PrAgU2/FP59 and PrAg/FP59 to AML cell lines HL60 
(A), Mono-Mac-6 (B), U937 (C), Mono-Mac-1 (D), ML-1 (E), TF1-vSrc (F), TF1-
HaRas (G) and ML-2 (H) using a proliferation inhibition assay (cytotoxicity). As 
illustrated, PrAgU2/FP59 is cytotoxic to all AML cell lines tested with the same potency 
(ML-2 and Mono-Mac-6) or a slightly lower one compared to the PrAg/FP59, the furin-
activated positive control. X-axis represents the log of the molar drug concentration; Y-
axis represents the cell viability expressed as optimal density at 450 nm. 
 
3.1.2  Effect of PrAgU2/FP59 on CD34
+
 human progenitor bone marrow blasts. 
 In order to determine whether the addition of a urokinase activation site in 
PrAgU2/FP59 increased its tumor selectivity we tested its cytotoxicity on CD34
+
 human 
progenitor bone marrow blasts and compared it with that of PrAg/FP59. As illustrated in 
Figure 3.1.2, PrAgU2/FP59 is not cytotoxic to CD34
+
 progenitor bone marrow blasts with 
an IC50 > 10,000 pM. In comparison, PrAg/FP59 was highly cytotoxic to CD34
+ 
blasts 
with an IC50 value of approximately 10 pM (table 3.1 and figure 3.1.2). This 
demonstrates that the addition of a urokinase-activation site in PrAgU2/FP59 drastically 
decreases its toxicity to normal, which, in turn, increases the tumor selectivity of this 
recombinant toxin. 
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Figure 3.1.2: Cytotoxicity of PrAgU2/FP59 and PrAg/FP59 to CD34
+
 progenitor bone 
marrow blasts using a proliferation-inhibition assay. As illustrated, CD34
+
 cells are 
sensitive to PrAg/FP59 but not to the urokinase-activated PrAgU2/FP59. On the X-axis 
represents the log of the molar drug concentration and the Y-axis represents cell viability 
expressed as optimal density at 450 nm. 
 
 
 
 
 
 
 
 
 
 
 
30 
 
Table 3.1 Sensitivity of AML cell lines and human CD34
+
 progenitor bone marrow 
blasts (normal bone marrow cells) to PrAgU2/FP59 and PrAg/FP59. 
 
Cells PrAgU2/FP59 (IC50;pmol/L) PrAg/FP59 (IC50;pmol/L) 
AML Cell lines   
HL60 3.0 46.0 
MonoMac-6 11.0 8.0 
ML-1 26.0 7.0 
ML-2 28.0 18.0 
MonoMac-1 86.0 29.0 
TF1-vRaf 134.4 9.0 
U937 160.0 2.0 
TF1-vSRC 359.0 11.0 
TF1-HaRas 414.0 16.0 
Normal Human Cells   
CD34
+
 Bone Marrow 
Blasts 
2842.0 10.0 
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3.2  Cell Cycle Analysis. 
  In order to determine whether, in addition to cytotoxicity, treatment with 
PrAgU2/FP59 induces cell cycle arrest in AML cell lines, we tested the cell cycle status 
of three AML cell lines ML-2, U937 and TF1-vRaf, at 48 hours following treatment, 
using flow cytometry. As expected, all the three cell lines had more than 45% of the 
cells in the G0/G1 phase, with 13 to 20% of the cells in the G2 phase and less than 2% 
of the cells are in pre-G0/G1 (dead) in untreated cells. Following treatment with the 
recombinant toxin PrAgU2/FP59, the percentage of living cells in both G0/G1 and G2 
phases decreased significantly to less than 13% of the cell population coupled to a 
dramatic increase in the percentage of cells in pre-G0/G1 ranging from 65% to 86% of 
the total cell population at both 24 and 48 hours post treatment (figure 3.2). This 
indicates that treatment with PrAgU2/FP59 has no impact on the cell cycle of AML cell 
lines but rather leads to complete cell death with no or a very small proportion of 
surviving cells. This also further demonstrates the significant potency of the cytotoxic 
effects of PrAgU2/FP59 to AML cell lines.  
 
 
A)  
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B)  
    
 
 
 
 
 
 
 
 
 
 
 
C)  
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Flow cytometry analysis of the effect of PrAgU2/FP59 on the cell cycle of 
three AML cells: ML-2 (A), TF1-vRaf (B), and U937 (C). The left panels show control 
cells and the right panels show cells treated with the recombinant toxin PrAgU2/FP59. 
G0/G1 cells are gated M1, G2 cells are gated M2 and pre-G0/G1 M3. Cells were gated 
on width versus forward scatter. 
 
 
3.3  Type of cell death following treatment with PrAgU2/FP59. 
     In order to determine the mechanisms leading to cell death in AML cells treated with 
the recombinant toxin PrAgU2/FP59, cells were stained with AnnexinV/PI and a cell 
permeable FITC-conjugated active caspase inhibitor and analyzed on flow cytometry. 
Treatment with different concentrations of PrAgU2/FP59 led to an increase in the 
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percentage of cells stained positively for annexinV associated with a very small increase 
in PI staining, at both 24 and 48 hours post-treatment, indicating that treatment with 
PrAgU2/FP59 induces apoptotic cell death in AML cell lines (figure 3.3). This was 
confirmed by AML cells staining positively with the FITC-labeled caspase inhibitor 
demonstrating the presence of active caspases in AML cells following treatment and 
further indicating that PrAgU2/FP59 induces apoptotic cell death in AML cell lines.  
 
 A)  
 
 
 
B) 
 
Figure 3.3: AnnexinV (FL1-H)/PI (FL2-H) staining of two AML cell lines TF1-vRaf 
(A) and U937 (B) treated with PrAgU2/FP59 for 48 hours and analyzed on flow 
cytometry. First panels from the left are control cells, second panels are cells treated 
with a low concentration (10
-10 
M) and the third panels are cells treated with a high 
concentration (10
-8
 M) of PrAgU2/FP59. The last panels to the right show a histogram of 
control cell (black) and treated cells (red) stained with a FITC-labeled cell permeable 
active caspase inhibitor clearly showing increased presence of active caspases in treated 
cells. Cells were gated in width versus forward scatter. 
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3.4  uPAR expression 
3.4.1  uPAR expression on AML cell lines 
     In order to further correlate the mechanisms of activation of PrAgU2/FP59 in AML 
cells to the expression levels of the urokinase plasminogen activator receptor (uPAR) on 
cells, we determined by flow cytometry uPAR expression levels on the entire panel of 
AML cell lines using cell surface staining with a FITC-labeled anti-uPAR antibody.  All 
stained AML cells were compared to the isotype control and expression levels were 
determined based on the ratio of fluorescence intensity (RFI) of stained and isotype 
control cells. All 9 AML cell lines stained positively for uPAR expression confirming 
that this cell surface serine protease is expressed on AML cells and is the underlying 
mechanism for the sensitivity of AML cells to the urokinase-activated PrAgU2/FP59 
(Figure 3.4.1 and Table 3.2). Of the 9 AML cell lines tested, 8 were found to highly 
express uPAR with a ratio of fluorescence intensity (RFI) ranging between 2.30 to 7.30 
with only one cell line, MonoMac-6, being weakly positive for uPAR expression with an 
RFI = 1.82 (figure 3.4.1 and table 3.2). The fact that MonoMac-6 cells, though low 
uPAR expressers, are still sensitive to PrAgU2/FP59 indicates that even low expression 
levels of uPAR are sufficient to generate enough urokinase activity to activate 
PrAgU2/FP59 and to selectively kill AML cells. 
 
 
 
35 
 
A)  
 
 
 
 
 
  
 
B)   
 
 
 
 
 
 
C)   
 
 
 
 
 
 
D)     
 
 
 
 
 
36 
 
 
E)     
 
 
 
 
 
 
F)     
 
 
 
 
 
 
G)    
 
 
 
 
 
 
H)     
  
 
 
37 
 
 
I)    
 
 
 
 
 
 
 
Figure 3.4.1: Flow cytometry analysis of a panel of 9 AML cell lines ML1 (A), 
MonoMac-1 (B), HL60 (C), ML-2 (D), Monomac-6 (E), U937 (F), TF1-vRaf (G), TF1-
vSrc (H) and TF1-HaRas (I) stained with a FITC-labeled anti-uPAR antibody and a 
FITC-labeled IgG isotype control. Left panels are cells stained with the isotypic control, 
middle panels are cells stained with anti-uPAR antibody, and right panels show a 
histogram of cells stained with the isotypic control (black) and cells stained with the 
anti-uPAR antibody (red). uPAR expression is considered positive when RFI > 1.5. 
Cells were gated on width versus forward scatter. 
 
 
3.4.2  uPAR expression on CD34
+
 cell line 
 
 As illustrated in figure 3.4.2 normal CD34
+
 progenitor bone marrow blasts, when 
examined using cell surface staining on flow cytometry, do not express uPAR having an 
RFI value of 1.15 indicating negative staining for uPAR expression. This confirms that 
the lack of sensitivity of CD34
+
 to PrAgU2/FP59 is due to the absence of uPAR receptors 
on their cell membrane surface, hence the toxin is not activated in these cells and it is 
selective to the AML cells that overexpress uPAR (table 3.2 and figure 3.4.2). 
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Figure 3.4.2: Flow cytometry analysis of CD34
+
 bone marrow blasts stained with a 
FITC-labeled anti-uPAR antibody and a FITC-labeled IgG isotype control. Left panels 
are cells stained with the isotypic control, middle panels are cells stained with anti-
uPAR antibody, and right panels show a histogram of cells stained with the isotypic 
control (black) and cells stained with the anti-uPAR antibody (red). uPAR expression is 
considered positive when RFI > 1.5. Cells were gated on width versus forward scatter. 
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Table 3.2: uPAR expression on AML cells and normal CD34
+
 bone marrow progenitor 
blasts. 
 
Cells uPAR expression level (RFI) PrAgU2/FP59 (IC50;pmol/L) 
AML Cell Lines   
MonoMac-6 1.82 (+) 11.0 
TF1-HaRas 2.30 (+) 414.0 
MonoMac-1 2.41 (+) 86.0 
TF1-vSRC 2.41 (+) 359.0 
TF1-vRaf 2.76 (+) 134.4 
ML-1 2.82 (+) 26.0 
ML-2 3.10 (+) 28.0 
HL60 3.25 (+) 3.0 
U937 7.29 (++) 2.0 
Normal Human 
Cells 
  
CD34
+
 1.15 (-) 3842.0 
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3.5  Blocking assays. 
     In order to demonstrate that the cell surface activity of the urokinase plasminogen 
activator system (uPA/uPAR) is essential for the activation and, subsequently, the 
potency of PrAgU2/FP59, we examined the effect of the inhibition of the uPA/uPAR 
system, using a neutralizing anti-uPA antibody, on the potency of PrAgU2/FP59 to AML 
cells. Three AML cell lines (Mono-Mac-1, Mono-Mac-6 and ML-2) were tested for their 
sensitivity to PrAgU2/FP59 in the presence and absence of the anti-uPA antibody. As 
illustrated in figure 3.5, inhibition of the uPA/uPAR system greatly reduced the potency 
of PrAgU2/FP59, with the reduction ranging from an increase in IC50 of 100-fold 
(Mono-Mac-6) and a 1000-fold (ML-2) in the presence of the antibody to the complete 
inhibition of the potency of the toxin (Mono-Mac-1). The difference in the extent of 
inhibition between the different cell lines is most likely due to the different levels of 
uPA secreted by each of them. Nevertheless, these results show that the inhibition of the 
uPA/uPAR system decreases the ability of cells to activate PrAgU2/FP59 and the 
subsequent potency of this toxin. This proves that an active uPA/uPAR system is 
essential for the potency of this urokinase-activated, tumor selective fusion toxin. 
 
A)   
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Figure 3.5: Cytotoxicity of PrAgU2/FP59 in the presence and absence of an anti-uPA to 
3 AML cell lines: MonoMac-1 (A), Monomac-6 (B) and ML-2 (C), using a proliferation 
inhibition assay. X-axis represents log of the molar drug concentration, Y-axis 
represents cell viability expressed as optimal density at 450 nm. 
 
 
3.6  Addition of exogenous pro-uPA 
In order to further confirm that the toxicity of PrAgU2/FP59 relies solely on the 
activation of the urokinase plasminogen receptor we compared the potency of 
PrAgU2/FP59 on U937 AML cell line in the presence and absence of exogenous pro-
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uPA. The active uPA cleaves the proenzyme plasminogen into active plasmin, which in 
turns activates uPA in a positive feedback loop (Prager et al., 2004) resulting the 
activation of PrAgU2/FP59 toxin. As shown in figure 3.6, the addition of exogeneous 
pro-uPA increased the conversion of pro-uPA to active uPA hence increasing the 
activity of urokinase system. Now that PrAgU2/FP59 is activated its toxicity level on 
U937 became higher. The presence of exogenous pro-uPA caused a 1000 folds reduction 
in IC50. This confirms that the activation of the uPA/uPAR system has a direct positive 
impact on the potency of this urokinase-selective toxin on all AML cell lines. 
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Figure 3.6: Cytotoxicity of PrAgU2/FP59 in the presence and absence of excess 
exogenous pro-uPA on U937 cells using a proliferation inhibition assay. X-axis 
represents log of the molar drug concentration, Y-axis represents cell viability expressed 
as optimal density at 450 nm. 
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CHAPTER FOUR 
DISCUSSION 
The uPA/uPAR system has been shown to be expressed in almost all types of 
human tumors such as carcinomas, sarcomas, monocytic and myelogenous leukemia. 
Since this particular system is poorly expressed in normal cells except in specific 
conditions such as tissue repair or remodeling, targeting the uPA/uPAR system could be 
a hallmark for different types of cancer (Liu et al., 2003). The poor prognosis of AML, 
the side effects of chemotherapeutic agents and the high mortality rates due to the 
development of resistance to the traditional chemotherapeutic drugs have led to 
identifying effective therapeutic drugs capable of targeting the resilient tumors without 
damaging normal tissue.  
One such targeted therapeutic drug, is the urokinase activated anthrax fusion 
toxin PrAgU2/FP59. This toxin is derived from anthrax lethal factor by first replacing 
the zinc metalloprotease domain of lethal factor on PrAg, the binding moiety of the 
anthrax lethal toxin, with a urokinase activation site. Also, the LF and EF binding site 
were substituted with the binding site of Pseudomonas aeruginosa exotoxin A, which is 
a protein synthesis inhibitor capable of causing cell death. By substituting its furin 
cleavage sequence with a urokinase specific cleavage sequence, the toxin PrAgU2/FP59 
becomes highly selective and potent (Abi-Habib et al., 2006). Targeting the urokinase 
system with fusion toxins is a novel approach in selectively targeting AML without 
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damaging DNA or blocking cell division, hence reducing drug side effect on normal 
organs (Wescott et al., 2004). A previous study was conducted to test the effect of 
recombinant toxins on AML. When diphtheria toxin furin cleavage site was replaced by 
a urokinase plasminogen activator cleavage site they obtained the DTU2GMCSF 
recombinant toxin. DTU2GMCSF has been shown to be highly potent against AML cells 
in vitro and highly selective since it did not induce liver damage in rats in vivo (Wescott 
et al., 2004). In a previous study we have shown that the fusion toxin PrAg/LF is highly 
cytotoxic against most AML cell lines through the LF-mediated inhibition of the MAPK 
pathway (Kassab et al., 2013). On the other hand, the potency and selectivity of 
PrAgU2/FP59 were tested on many human tumor cell types: it was shown that many 
non-small cell lung cancer, pancreatic cancer, colon cancer, prostate cancer, and breast 
cancer cells all overexpress the urokinase plasminogen activator receptors on their cell 
surface hence these cell types were highly sensitive to the potent the drug PrAgU2/FP59. 
In the same study, this potent drug was not cytotoxic to normal cells such as human lung 
fibroblasts, human cardiomyocytes, human cardiac microvascular endothelial cells, renal 
proximal tubule epithelial cells and renal cortical epithelial cells (Abi Habib et al., 
2006). We also tested the pathogenicity of PrAg/LF and PrAgU2/LF on Balb/c mice in 
vivo and found that the addition of the urokinase plasminogen activator system highly 
reduced the damaging effect of the toxin on internal organs. Since different experiments 
have shown that PrAgU2/FP59 is capable of selectively successfully targeting the 
overexpressed urokinase system, and since recent studies have shown that more than 
70% of AML patients express the uPA protease system, therefore this drug can be used 
for AML treatment.  
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In this study, we tested 9 AML cell lines’ sensitivity to PrAgU2/FP59 using a 
proliferation inhibition assay, and all cell lines were found to be sensitive (IC50 < 400 
pmol/L). Knowing that FP59 cannot inhibit protein synthesis unless the urokinase 
system has been activated, these results suggested that all tested AML cell lines express 
the uPA protease system. These results are in line with a previous study that shows that 
PrAgU2/FP59 is highly activated in cancer cells since they overexpress the uPAR, thus 
this toxin can be used in targeted molecular therapy against AML.  The human bone 
marrow progenitor blasts CD34
+
 are very sensitive to PrAg/FP59, but when the drug was 
made more selective, this normal human cell line treated with PrAgU2/FP59 using a 
proliferation inhibition assay was not sensitive to protein synthesis inhibition having an 
IC50 4X folds greater than the normal range (IC50 >700 pmol/L). Moreover, in a previous 
study treating most normal human cell lines with this engineered recombinant toxin was 
proven to be very safe. We further examined the uPAR level of expression on the 
extracellular surface of cells and showed that it is highly expressed on AML cells but not 
on CD34
+
. Upon adding anti-uPA to AML cell lines, they became resistant to the toxin 
confirming that uPAR is indispensable for the activation of PrAgU2/FP59, and without 
it, the recombinant toxin is not toxic at all. This explains the sensitivity of CD34
+
 to 
PrAg/FP59 and not to PrAgU2/FP59, since the latter toxin was not activated due to the 
absence of sufficient uPA receptors on the cell membrane. Since we have shown that the 
lack of the recombinant toxin activation on CD34
+
 cell line is due to the absence of 
urokinase receptor and in previous studies it has been shown that most human cell lines 
do not express the uPA protease system unless under specific conditions, we then 
assumed that different types of human cells are also resistant to the recombinant toxin 
PrAgU2/FP59. This was shown with U937 AML cell line which exhibits a high increase 
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in sensitivity to PrAgU2/FP59 upon addition of exogenous pro-uPA which highly 
increases the activity of uPA receptors on its cell surface. Therefore, any AML cell line 
that does not overexpress uPA will still be sensitive to the toxin by activating the 
uPA/uPAR system with the uPA secreted by neighboring leukemic cells. The selectivity 
of this toxin to AML cells only makes it a drug of choice since it will minimize all the 
side effects caused by current chemotherapeutic drugs, and since this targeted therapy 
relies on the overexpression of the uPA/uPAR system which is found on all AML cells, 
we suspect that the number of relapsing patients will reduce. Furthermore, we 
demonstrated that the reduction in proliferation of most AML cells is due to cell death 
rather than cell cycle arrest, using propidium iodide staining with flow cytometry. 
Additionally, we have revealed that the treated AML cells have an increase in annexin V 
staining, revealing apoptotic rather than necrotic cell death. PrAgU2/FP59 has proved the 
ability to treat AML by triggering cell death without being able to induce the same 
mechanism in normal cells. Therefore, PrAgU2/FP59 could be considered as a potential 
hallmark for the treatment of AML by selectively targeting the cancerous cells and 
initiating apoptosis without affecting normal cells. 
In a previous in vivo study on Balb/c mice, we have shown that adding the 
urokinase moiety to the toxin PrAg/LF had a great impact on reducing its effect on 
normal cells even if used at high doses. Since FP59 is more potent than LF in causing 
cell degeneration, thus performing an in vivo study would probably have a selective 
effect on AML cells without causing organ deterioration because of the presence of the 
selective urokinase moiety in the toxin.  
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